Member Info for metis20

From yesterday's RNS - timescale for completion of required studies for FDA submission - "ANGLE is working towards an FDA clearance of the Parsortix system in metastatic breast cancer with the required analytical and clinical studies targeted for completion by 30 June 2018. ANGLE is seeking to become the first company ever to receive FDA clearance for a medical device to harvest cancer cells from patient blood for subsequent analysis."

On Friday 27 October 2017 Sara Cockerill QC, sitting as a Judge in the High Court of Justice of England and Wales, ordered that the application brought by Ukraine seeking to set aside the recent Uncitral arbitration award against Ukraine and in favour of JKX be dismissed. The Government of Ukraine is accordingly therefore still liable to pay to JKX the sum of USD11.8 million plus interest and costs of USD0.3 million in relation to subsidiary claims, as previously ordered. The Judge also ordered that Ukraine should pay JKX's costs of �61,908.65 within 14 days.

Yes - into my Interactive Investor account yesterday.

Yesterday's drop was a tree-shake to fill a large order - 118k at 926p were reported around 16:20 yesterday - about �1.1mn buy. Currently midprice 939p with level 2 looking strong ahead of Q3 trading update due next Tuesday. "Plus500, a leading online service provider for retail customers to trade CFDs internationally, is pleased to announce that its business continues to trade strongly. Accordingly, the Board anticipates that revenues and profits for the year ending 31 December 2017 will be ahead of market expectations. Further details will be announced in the Company's scheduled third quarter trading update which will be issued on 31 October 2017."

Details of the move from expensive plastic liner to locally sourced clay is detailed in the latest presentation - https://www.investegate.co.uk/salt-lake-potash-ltd--so4-/rns/company-presentation/201710230852393171U/ Good to see that sulphate not chloride is the target product. Costs look to be very competitive. Lombard Otler went from 7.73% to 8.85% on Friday. https://www.investegate.co.uk/salt-lake-potash-ltd--so4-/rns/holding-s--in-company/201710230902493175U/

see page 12 of the 2016 Annual Report for an overall picture of the effectiveness of PLUS500's Risk Management Framework https://cdn.plus500.com/media/Investors/Reports/Plus500_Annual_Report_16.pdf

purchase this am - a very reassuring shape to the 3 year chart - momentum beckons. Surprised by lack of reaction to that positive July trading update https://www.investegate.co.uk/dotdigital-group-plc--dotd-/rns/trading-update/201707180700063040L/ Full year results due in mid-October

From the 24 April 2014 RNS - “…and effective environmental cleaning. To achieve the latter, the Trust deployed Tristel's Jet trigger spray gel for areas close to the patient and Tristel Fuse for larger surface areas. Both products are rapidly effective against bacteria, fungi, viruses, mycobacteria and crucially spores. As a result of the campaign every ward in the Trust has been C. diff free for a period of at least 100 days, 95% of all wards have been C. diff free for 200 days and 14 wards have achieved a year clear. The Trust's Infection Prevention team has received the accolade of national hospital team of the year from the UK Infection Prevention Society.” https://www.investegate.co.uk/tristel-plc--tstl-/rns/success-in-controlling-clostridium-difficile-rates/201404240700173686F/

"Japanese fungus" - What will be used to deep clean infected areas? http://www.telegraph.co.uk/news/2017/08/14/safety-alert-drug-resistant-japanese-fungus-found-55-uk-hospitals/

From Proactive Investor - In an initial note to clients, analysts at Liberum Capital hiked their target price for Plus 500 shares to 992p, up from 628p previously, and reiterated a ‘buy’ rating on the stock. They said: “We remain cognizant of the regulatory challenges facing the industry, which we acknowledge may put our forecasts from CY18 at risk. “However, we believe Plus500 is continuing to prove very capable of adapting to changes in its markets.”

Having announced a share buy back programme on 2 June 2017 of $10 million through 31 August 2017 (of which $ 6.87 million has been completed as of 4 August 2017), the Board is pleased to announce an additional share buy back programme to purchase up to $27.21 million of the Company's shares. This makes a total of $37.21 million for the two buy backs. The additional buy back programme will run from the date of this announcement to 1 February 2018.

Current buy back $10mn. Announced today a further buy back of $27.21mn. The same sum as is being paid out for the Interims divi, Interims divi. of about 2.8%

Share repurchase so far published - In summary roughly 2/3 of the way through the share repurchase both in terms of time and cash. Detail – from today’s RNS “excluding 857,781 Shares held as treasury shares” 857k shares bought back at a cost of £4.91mn (excluding expenses) of the £7.7mn allocated to the share repurchase. That is 64% of the share repurchase cash used up – but that calculation does not include share repurchase expenses. 42 trading days gone - another 22 to go to August 31st - so 66% of the possible trading days allocated have passed.

FROM todays RNS - "Alpha FX (AIM:AFX) confirms today that its wholly owned subsidiary, Alpha FX Limited, has been authorised by the Financial Conduct Authority (FCA) as a BIPRU investment firm with immediate effect. As set out in the Group's Admission document, in January 2017 the Company applied to the FCA to become a BIPRU investment firm. The Company's status as a BIPRU investment firm will enable it to offer currency swaps and options to its clients, in addition to its existing products and services." https://www.investegate.co.uk/alpha-fx-group-plc--afx-/rns/alpha-authorised-by-fca-as-bipru-investment-firm/201708011410537774M/

http://www.tristel.com/sites/default/files/2017_investor_day_presentation_with_script.pdf

From today's excellent trading update RNS "For the year ended 30 June 2017 Tristel will record turnover in excess of £20 million (2016: £17.1 million) and pre-tax profit (before share-based payments) of at least £4 million (2016: £3.3 million). Both turnover and pre-tax profit are ahead of market expectations. In the second half, revenue from overseas markets contributed 50% of the Group total compared to 43% in the first half, and for the full year overseas revenue represented 47% of Group revenue - a record level." https://www.investegate.co.uk/tristel-plc--tstl-/rns/trading-update---notice-of-results/201707190700024226L/

Potentially misleading reference to Sophos and the NHS cyber attack in today's Telegraph by Frank Talbot of Citywire. He should have read this Telegraph article - hTtp://www.telegraph.co.uk/business/2017/05/17/sophos-outpaces-growth-targets-nhs-cyber-attack-boosts-prospects/ where he would have seen - "Mr Bray said the company does provide cyber security services to some NHS trusts and that they had been unaffected by the ransomware operation."

and this from Forbes https://www.forbes.com/sites/rogeraitken/2017/06/29/ethernity-networks-oversubscribed-placing-puts-58m-market-cap-on-tech-game-changer/#f9d897730035

via http://www.ethernitynet.com/ - Investors - Regulatory and Financial Documents - Admission Document

https://finance.yahoo.com/news/ethernity-networks-announces-admission-aim-150900374.html